Cognition Therapeutics(US:CGTX) Globenewswire·2026-03-23 11:30Core Viewpoint - Cognition Therapeutics, Inc. is set to release its financial results for Q4 and the full year ended December 31, 2025, on March 26, 2026, before market opening, followed by a conference call to discuss these results and provide a business update [1]. Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, aiming to provide effective therapies for conditions such as dementia with Lewy bodies, Alzheimer's disease, and Parkinson's disease [3]. - The company's lead candidate, zervimesine (CT1812), is an investigational oral therapy that has shown promise in Phase 2 clinical trials for DLB and mild-to-moderate Alzheimer's disease [3]. - The company has received nearly $200 million in grants from the National Institutes of Health and related foundations to support its clinical research efforts [3]. Conference Call Information - The conference call to discuss the financial results can be accessed by dialing (800) 445-7795 for U.S. participants or (785) 424-1699 for international participants, using conference ID number CGTXQ4 [2]. - A live webcast with Q&A will be available on the company's website, and an archive of the webcast will be accessible for 90 days starting from March 26, 2026 [2].